• About WordPress
    • WordPress.org
    • Documentation
    • Learn WordPress
    • Support
    • Feedback
  • Log In
  • Request Membership
Skip to content
Medxy AI Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • ADP-A2AFP
Innovative TCR T-Cell Therapy Shows Promise in Advanced Hepatocellular and Gastric Hepatoid Carcinoma
Posted inGastroenterology news Oncology

Innovative TCR T-Cell Therapy Shows Promise in Advanced Hepatocellular and Gastric Hepatoid Carcinoma

Posted by By MedXY 10/28/2025
A phase I trial reveals that ADP-A2AFP TCR T-cell therapy, targeting AFP-expressing advanced hepatocellular carcinoma and gastric hepatoid carcinoma, is safe and exhibits early antitumor activity in patients refractory to conventional treatments.
Read More
  • Sustained Impact of Lifestyle and Metformin Interventions on Type 2 Diabetes Prevention: Insights from 21 Years of the US DPP Trial
  • Evaluating AI-Led vs Human-Led Lifestyle Interventions in Prediabetes: Evidence from a Randomized Clinical Trial of the Diabetes Prevention Program
  • Venomous Snakes and Snakebites in the US: What You Need to Know to Stay Safe
  • Elafibranor Shows Promise as a Safe and Effective Therapy for Primary Sclerosing Cholangitis: Insights from the Phase II ELMWOOD Trial
  • Apixaban Versus Aspirin for Recurrent Stroke Prevention in Patients with Left Ventricular Dysfunction: Insights from a Secondary Analysis of the ARCADIA Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation blood pressure breast cancer cardiovascular disease cardiovascular health cardiovascular risk clinical trial clinical trials depression diabetes diet epidemiology exercise gut microbiota health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Physical Activity Pregnancy prevention prognosis public health randomized clinical trial randomized controlled trial randomized trial sexual health targeted therapy treatment type 2 diabetes weight loss wellness women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top
Sign in